» Articles » PMID: 37525025

Increasing Rigor of Preclinical Research to Maximize Opportunities for Translation

Overview
Specialty Neurology
Date 2023 Jul 31
PMID 37525025
Authors
Affiliations
Soon will be listed here.
Abstract

The use of animal models in pre-clinical research has significantly broadened our understanding of the pathologies that underlie traumatic brain injury (TBI)-induced damage and deficits. However, despite numerous pre-clinical studies reporting the identification of promising neurotherapeutics, translation of these therapies to clinical application has so far eluded the TBI research field. A concerted effort to address this lack of translatability is long overdue. Given the inherent heterogeneity of TBI and the replication crisis that continues to plague biomedical research, this is a complex task that will require a multifaceted approach centered around rigor and reproducibility. Here, we discuss the role of three primary focus areas for better aligning pre-clinical research with clinical TBI management. These focus areas are (1) reporting and standardization of protocols, (2) replication of prior knowledge including the confirmation of expected pharmacodynamics, and (3) the broad application of open science through inter-center collaboration and data sharing. We further discuss current efforts that are establishing the core framework needed for successfully addressing the translatability crisis of TBI.

Citing Articles

Editorial: Revisiting mouse models of traumatic brain injuries: a focus on intracellular mechanisms.

Omais S, Kobeissy F, Zibara K, Shaito A Front Cell Neurosci. 2024; 18:1505348.

PMID: 39484181 PMC: 11524986. DOI: 10.3389/fncel.2024.1505348.


A Systematic Review of Traumatic Brain Injury in Modern Rodent Models: Current Status and Future Prospects.

Balakin E, Yurku K, Fomina T, Butkova T, Nakhod V, Izotov A Biology (Basel). 2024; 13(10).

PMID: 39452122 PMC: 11504108. DOI: 10.3390/biology13100813.


Calcium and Non-Penetrating Traumatic Brain Injury: A Proposal for the Implementation of an Early Therapeutic Treatment for Initial Head Insults.

ODay D Biomolecules. 2024; 14(7).

PMID: 39062567 PMC: 11274459. DOI: 10.3390/biom14070853.


Pharmacotherapy for Traumatic Brain Injury: The Next Generation of Clinical Trials.

Diaz-Arrastia R, Kochanek P Neurotherapeutics. 2023; 20(6):1428-1432.

PMID: 37698808 PMC: 10684833. DOI: 10.1007/s13311-023-01438-5.

References
1.
Jarrahi A, Braun M, Ahluwalia M, Gupta R, Wilson M, Munie S . Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions. Biomedicines. 2020; 8(10). PMC: 7601301. DOI: 10.3390/biomedicines8100389. View

2.
Katada R, Nishitani Y, Honmou O, Okazaki S, Houkin K, Matsumoto H . Prior ethanol injection promotes brain edema after traumatic brain injury. J Neurotrauma. 2009; 26(11):2015-25. DOI: 10.1089/neu.2008.0552. View

3.
Stein D . Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials. Brain Inj. 2015; 29(11):1259-72. PMC: 4667711. DOI: 10.3109/02699052.2015.1065344. View

4.
Nielson J, Cooper S, Yue J, Sorani M, Inoue T, Yuh E . Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis. PLoS One. 2017; 12(3):e0169490. PMC: 5336356. DOI: 10.1371/journal.pone.0169490. View

5.
Menon D . Unique challenges in clinical trials in traumatic brain injury. Crit Care Med. 2008; 37(1 Suppl):S129-35. DOI: 10.1097/CCM.0b013e3181921225. View